Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events
Since 1996, the scientific community has become aware of 14 reports of yellow fever vaccine (YEL)-associated viscerotropic disease (YEL-AVD) cases and four reports of YEL-associated neurotropic disease (YEL-AND) worldwide, changing our understanding of the risks of the vaccine. Based on 722 adverse...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2005-05, Vol.23 (25), p.3256-3263 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3263 |
|---|---|
| container_issue | 25 |
| container_start_page | 3256 |
| container_title | Vaccine |
| container_volume | 23 |
| creator | Khromava, Alena Y. Eidex, Rachel Barwick Weld, Leisa H. Kohl, Katrin S. Bradshaw, Robert D. Chen, Robert T. Cetron, Martin S. |
| description | Since 1996, the scientific community has become aware of 14 reports of yellow fever vaccine (YEL)-associated viscerotropic disease (YEL-AVD) cases and four reports of YEL-associated neurotropic disease (YEL-AND) worldwide, changing our understanding of the risks of the vaccine. Based on 722 adverse event reports after YEL submitted to the U.S. Vaccine Adverse Event Reporting System in 1990–2002, we updated the estimates of the age-adjusted reporting rates of serious adverse events, YEL-AVD and YEL-AND. We found that the reporting rates of serious adverse events were significantly higher among vaccinees aged ≥60 years than among those 19–29 years of age (reporting rate ratio
=
5.9, 95% CI 1.6–22.2). Yellow fever is a serious and potentially fatal disease. For elderly travelers, the risk for severe illness and death due to yellow fever infection should be balanced against the risk of a serious adverse event due to YEL. |
| doi_str_mv | 10.1016/j.vaccine.2005.01.089 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67760800</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X05001283</els_id><sourcerecordid>3420728801</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-8be086e83d15597335c0e9ce6a3bfe38123489fe3d2d0ad4aa392babd2f0219b3</originalsourceid><addsrcrecordid>eNqFkU-LFDEQxYMo7rj6EZSA6K17K0n_Sbwsy6LuwsJeFPQU0kn1knGme0x1j_jtTTMNC172EBIqv3pUvcfYWwGlANFcbMuj8z4OWEqAugRRgjbP2EboVhWyFvo524BsqqIS8OOMvSLaQgaVMC_Zmai1aqWCDXv4ibvd-If3eMTEV8lP_Grg8yG4CQN3REi0x2HiY89dOLrBL-UHzF_c8RTpF--dn8bE-3wIUxxnWkhMhDwLDxO9Zi96tyN8s97n7PuXz9-ub4q7-6-311d3ha-MmQrdIegGtQqirk2rVO0BjcfGqa5HpYVUlTb5FWQAFyrnlJGd64LsQQrTqXP28aR7SOPvGWmy-0g-7-gGzFPZpm0b0ABPgiL70xopM_j-P3A7zmnIS9hlRmgrqBa5-kT5NBIl7O0hxb1Lf60AuwRmt3Z11y6BWRA2B5b73q3qc7fH8Ni1JpSBDyvgyLtdn7L9kR65ttamatrMXZ44zO4eIyZLPuISVUzoJxvG-MQo_wBUOrYz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1559074040</pqid></control><display><type>article</type><title>Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Khromava, Alena Y. ; Eidex, Rachel Barwick ; Weld, Leisa H. ; Kohl, Katrin S. ; Bradshaw, Robert D. ; Chen, Robert T. ; Cetron, Martin S.</creator><creatorcontrib>Khromava, Alena Y. ; Eidex, Rachel Barwick ; Weld, Leisa H. ; Kohl, Katrin S. ; Bradshaw, Robert D. ; Chen, Robert T. ; Cetron, Martin S. ; The Yellow Fever Vaccine Safety Working Group ; Yellow Fever Vaccine Safety Working Group</creatorcontrib><description>Since 1996, the scientific community has become aware of 14 reports of yellow fever vaccine (YEL)-associated viscerotropic disease (YEL-AVD) cases and four reports of YEL-associated neurotropic disease (YEL-AND) worldwide, changing our understanding of the risks of the vaccine. Based on 722 adverse event reports after YEL submitted to the U.S. Vaccine Adverse Event Reporting System in 1990–2002, we updated the estimates of the age-adjusted reporting rates of serious adverse events, YEL-AVD and YEL-AND. We found that the reporting rates of serious adverse events were significantly higher among vaccinees aged ≥60 years than among those 19–29 years of age (reporting rate ratio
=
5.9, 95% CI 1.6–22.2). Yellow fever is a serious and potentially fatal disease. For elderly travelers, the risk for severe illness and death due to yellow fever infection should be balanced against the risk of a serious adverse event due to YEL.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2005.01.089</identifier><identifier>PMID: 15837230</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Adverse drug reaction reporting systems ; Age ; Age Factors ; Age groups ; Aged ; Applied microbiology ; Arboviroses ; Armed forces ; Biological and medical sciences ; Cardiovascular disease ; Child ; Child, Preschool ; Confidence intervals ; Disease control ; Family medical history ; Female ; Fever ; Fundamental and applied biological sciences. Psychology ; Hepatitis ; Hepatitis A Vaccines - adverse effects ; Human viral diseases ; Humans ; Infant ; Infectious diseases ; Logistic Models ; Male ; Medical sciences ; Microbiology ; Middle Aged ; Military Personnel ; Nervous System Diseases - etiology ; Population Surveillance ; Ratios ; Risk Factors ; Travel ; Tropical viral diseases ; Typhoid-Paratyphoid Vaccines - adverse effects ; United States - epidemiology ; Vaccination/adverse effects ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vector-borne diseases ; Viral diseases ; Yellow fever ; Yellow fever vaccine ; Yellow Fever Vaccine - adverse effects ; Yellow fever virus</subject><ispartof>Vaccine, 2005-05, Vol.23 (25), p.3256-3263</ispartof><rights>2005 Elsevier Ltd</rights><rights>2006 INIST-CNRS</rights><rights>Copyright Elsevier Limited May 9, 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-8be086e83d15597335c0e9ce6a3bfe38123489fe3d2d0ad4aa392babd2f0219b3</citedby><cites>FETCH-LOGICAL-c499t-8be086e83d15597335c0e9ce6a3bfe38123489fe3d2d0ad4aa392babd2f0219b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1559074040?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17589467$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15837230$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khromava, Alena Y.</creatorcontrib><creatorcontrib>Eidex, Rachel Barwick</creatorcontrib><creatorcontrib>Weld, Leisa H.</creatorcontrib><creatorcontrib>Kohl, Katrin S.</creatorcontrib><creatorcontrib>Bradshaw, Robert D.</creatorcontrib><creatorcontrib>Chen, Robert T.</creatorcontrib><creatorcontrib>Cetron, Martin S.</creatorcontrib><creatorcontrib>The Yellow Fever Vaccine Safety Working Group</creatorcontrib><creatorcontrib>Yellow Fever Vaccine Safety Working Group</creatorcontrib><title>Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Since 1996, the scientific community has become aware of 14 reports of yellow fever vaccine (YEL)-associated viscerotropic disease (YEL-AVD) cases and four reports of YEL-associated neurotropic disease (YEL-AND) worldwide, changing our understanding of the risks of the vaccine. Based on 722 adverse event reports after YEL submitted to the U.S. Vaccine Adverse Event Reporting System in 1990–2002, we updated the estimates of the age-adjusted reporting rates of serious adverse events, YEL-AVD and YEL-AND. We found that the reporting rates of serious adverse events were significantly higher among vaccinees aged ≥60 years than among those 19–29 years of age (reporting rate ratio
=
5.9, 95% CI 1.6–22.2). Yellow fever is a serious and potentially fatal disease. For elderly travelers, the risk for severe illness and death due to yellow fever infection should be balanced against the risk of a serious adverse event due to YEL.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adverse drug reaction reporting systems</subject><subject>Age</subject><subject>Age Factors</subject><subject>Age groups</subject><subject>Aged</subject><subject>Applied microbiology</subject><subject>Arboviroses</subject><subject>Armed forces</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular disease</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Confidence intervals</subject><subject>Disease control</subject><subject>Family medical history</subject><subject>Female</subject><subject>Fever</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Hepatitis</subject><subject>Hepatitis A Vaccines - adverse effects</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infant</subject><subject>Infectious diseases</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Military Personnel</subject><subject>Nervous System Diseases - etiology</subject><subject>Population Surveillance</subject><subject>Ratios</subject><subject>Risk Factors</subject><subject>Travel</subject><subject>Tropical viral diseases</subject><subject>Typhoid-Paratyphoid Vaccines - adverse effects</subject><subject>United States - epidemiology</subject><subject>Vaccination/adverse effects</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vector-borne diseases</subject><subject>Viral diseases</subject><subject>Yellow fever</subject><subject>Yellow fever vaccine</subject><subject>Yellow Fever Vaccine - adverse effects</subject><subject>Yellow fever virus</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkU-LFDEQxYMo7rj6EZSA6K17K0n_Sbwsy6LuwsJeFPQU0kn1knGme0x1j_jtTTMNC172EBIqv3pUvcfYWwGlANFcbMuj8z4OWEqAugRRgjbP2EboVhWyFvo524BsqqIS8OOMvSLaQgaVMC_Zmai1aqWCDXv4ibvd-If3eMTEV8lP_Grg8yG4CQN3REi0x2HiY89dOLrBL-UHzF_c8RTpF--dn8bE-3wIUxxnWkhMhDwLDxO9Zi96tyN8s97n7PuXz9-ub4q7-6-311d3ha-MmQrdIegGtQqirk2rVO0BjcfGqa5HpYVUlTb5FWQAFyrnlJGd64LsQQrTqXP28aR7SOPvGWmy-0g-7-gGzFPZpm0b0ABPgiL70xopM_j-P3A7zmnIS9hlRmgrqBa5-kT5NBIl7O0hxb1Lf60AuwRmt3Z11y6BWRA2B5b73q3qc7fH8Ni1JpSBDyvgyLtdn7L9kR65ttamatrMXZ44zO4eIyZLPuISVUzoJxvG-MQo_wBUOrYz</recordid><startdate>20050509</startdate><enddate>20050509</enddate><creator>Khromava, Alena Y.</creator><creator>Eidex, Rachel Barwick</creator><creator>Weld, Leisa H.</creator><creator>Kohl, Katrin S.</creator><creator>Bradshaw, Robert D.</creator><creator>Chen, Robert T.</creator><creator>Cetron, Martin S.</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7U2</scope><scope>7X8</scope></search><sort><creationdate>20050509</creationdate><title>Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events</title><author>Khromava, Alena Y. ; Eidex, Rachel Barwick ; Weld, Leisa H. ; Kohl, Katrin S. ; Bradshaw, Robert D. ; Chen, Robert T. ; Cetron, Martin S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-8be086e83d15597335c0e9ce6a3bfe38123489fe3d2d0ad4aa392babd2f0219b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adverse drug reaction reporting systems</topic><topic>Age</topic><topic>Age Factors</topic><topic>Age groups</topic><topic>Aged</topic><topic>Applied microbiology</topic><topic>Arboviroses</topic><topic>Armed forces</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular disease</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Confidence intervals</topic><topic>Disease control</topic><topic>Family medical history</topic><topic>Female</topic><topic>Fever</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Hepatitis</topic><topic>Hepatitis A Vaccines - adverse effects</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infant</topic><topic>Infectious diseases</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Military Personnel</topic><topic>Nervous System Diseases - etiology</topic><topic>Population Surveillance</topic><topic>Ratios</topic><topic>Risk Factors</topic><topic>Travel</topic><topic>Tropical viral diseases</topic><topic>Typhoid-Paratyphoid Vaccines - adverse effects</topic><topic>United States - epidemiology</topic><topic>Vaccination/adverse effects</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vector-borne diseases</topic><topic>Viral diseases</topic><topic>Yellow fever</topic><topic>Yellow fever vaccine</topic><topic>Yellow Fever Vaccine - adverse effects</topic><topic>Yellow fever virus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khromava, Alena Y.</creatorcontrib><creatorcontrib>Eidex, Rachel Barwick</creatorcontrib><creatorcontrib>Weld, Leisa H.</creatorcontrib><creatorcontrib>Kohl, Katrin S.</creatorcontrib><creatorcontrib>Bradshaw, Robert D.</creatorcontrib><creatorcontrib>Chen, Robert T.</creatorcontrib><creatorcontrib>Cetron, Martin S.</creatorcontrib><creatorcontrib>The Yellow Fever Vaccine Safety Working Group</creatorcontrib><creatorcontrib>Yellow Fever Vaccine Safety Working Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Safety Science and Risk</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khromava, Alena Y.</au><au>Eidex, Rachel Barwick</au><au>Weld, Leisa H.</au><au>Kohl, Katrin S.</au><au>Bradshaw, Robert D.</au><au>Chen, Robert T.</au><au>Cetron, Martin S.</au><aucorp>The Yellow Fever Vaccine Safety Working Group</aucorp><aucorp>Yellow Fever Vaccine Safety Working Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2005-05-09</date><risdate>2005</risdate><volume>23</volume><issue>25</issue><spage>3256</spage><epage>3263</epage><pages>3256-3263</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Since 1996, the scientific community has become aware of 14 reports of yellow fever vaccine (YEL)-associated viscerotropic disease (YEL-AVD) cases and four reports of YEL-associated neurotropic disease (YEL-AND) worldwide, changing our understanding of the risks of the vaccine. Based on 722 adverse event reports after YEL submitted to the U.S. Vaccine Adverse Event Reporting System in 1990–2002, we updated the estimates of the age-adjusted reporting rates of serious adverse events, YEL-AVD and YEL-AND. We found that the reporting rates of serious adverse events were significantly higher among vaccinees aged ≥60 years than among those 19–29 years of age (reporting rate ratio
=
5.9, 95% CI 1.6–22.2). Yellow fever is a serious and potentially fatal disease. For elderly travelers, the risk for severe illness and death due to yellow fever infection should be balanced against the risk of a serious adverse event due to YEL.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>15837230</pmid><doi>10.1016/j.vaccine.2005.01.089</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2005-05, Vol.23 (25), p.3256-3263 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67760800 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
| subjects | Adolescent Adult Adverse drug reaction reporting systems Age Age Factors Age groups Aged Applied microbiology Arboviroses Armed forces Biological and medical sciences Cardiovascular disease Child Child, Preschool Confidence intervals Disease control Family medical history Female Fever Fundamental and applied biological sciences. Psychology Hepatitis Hepatitis A Vaccines - adverse effects Human viral diseases Humans Infant Infectious diseases Logistic Models Male Medical sciences Microbiology Middle Aged Military Personnel Nervous System Diseases - etiology Population Surveillance Ratios Risk Factors Travel Tropical viral diseases Typhoid-Paratyphoid Vaccines - adverse effects United States - epidemiology Vaccination/adverse effects Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vector-borne diseases Viral diseases Yellow fever Yellow fever vaccine Yellow Fever Vaccine - adverse effects Yellow fever virus |
| title | Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T12%3A53%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Yellow%20fever%20vaccine:%20An%20updated%20assessment%20of%20advanced%20age%20as%20a%20risk%20factor%20for%20serious%20adverse%20events&rft.jtitle=Vaccine&rft.au=Khromava,%20Alena%20Y.&rft.aucorp=The%20Yellow%20Fever%20Vaccine%20Safety%20Working%20Group&rft.date=2005-05-09&rft.volume=23&rft.issue=25&rft.spage=3256&rft.epage=3263&rft.pages=3256-3263&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2005.01.089&rft_dat=%3Cproquest_cross%3E3420728801%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1559074040&rft_id=info:pmid/15837230&rft_els_id=S0264410X05001283&rfr_iscdi=true |